Erlotinib

Tarceva

Brand for: Erlotinib

CVS logo
CVS
$7,124.01
Walgreens logo
Walgreens
Pay Online$84.00
Albertsons logo
Albertsons
$1,048.79
Walmart logo
Walmart
$6,822.82
Show this card to your pharmacist

Tarceva Savings card

$84.00

BIN
019876
ID
LHE110CE17
PCN
CHIPPO
GRP
LHX

Print or send this coupon to your phone

About Tarceva

Drug Details

Erlotinib, marketed as Tarceva, is an oral medication prescribed for the treatment of specific types of cancer, including non-small cell lung cancer (NSCLC) and pancreatic cancer. It is particularly used in adults with metastatic NSCLC and in combination with gemcitabine (Gemzar) for advanced, unresectable, or metastatic pancreatic cancer. As a tyrosine kinase inhibitor, erlotinib targets and inhibits the activity of the epidermal growth factor receptor (EGFR) on cancer cells. EGFR plays a crucial role in cell growth, and cancer cells typically have more of these receptors than normal cells. By blocking EGFR, erlotinib effectively hampers the growth and spread of cancer cells. While erlotinib is a recommended treatment for certain adults, it can often lead to side effects such as skin rashes and diarrhea. It is important for patients to discuss any concerns with their healthcare provider before beginning treatment to ensure it is safe and suitable for their condition.

Related Prescriptions

Tarceva (Erlotinib) dosage forms

DosageQuantityPrice fromPer unit
100MG30 Tablets$84.00$2.80
150MG30 Tablets$100.80$3.36

Tarceva FAQs

Tarceva (erlotinib) has not been discontinued. It is still available and used in the treatment of certain types of cancer, such as non-small cell lung cancer and pancreatic cancer. However, there may be specific circumstances or regions where availability is affected due to regulatory decisions, market demand, or other factors. It is important for patients to consult with their healthcare provider for the most current information regarding their treatment options.

Tarceva is used for the treatment of certain types of non-small cell lung cancer (NSCLC) and pancreatic cancer. It is typically prescribed for patients whose cancer has spread to other parts of the body and is used when other treatments have not been effective.

The choice between Tagrisso (osimertinib) and Tarceva (erlotinib) depends on several factors, including the specific type of EGFR mutation present in the cancer, the stage of the disease, and the patient's overall health condition. Tagrisso is often preferred for patients with non-small cell lung cancer (NSCLC) that has a specific EGFR T790M mutation or as a first-line treatment for certain types of EGFR mutations. It is known for its efficacy in crossing the blood-brain barrier, which can be beneficial in cases with brain metastases. However, the decision should be made by the healthcare provider based on the individual patient's clinical scenario.

The most common side effect of erlotinib is a skin rash.

Erlotinib can cause several toxicities, including rash, diarrhea, fatigue, and anorexia. Other potential side effects include interstitial lung disease, hepatotoxicity, and gastrointestinal perforation. Patients may also experience nausea, vomiting, and ocular disorders. It is important for patients to be monitored regularly for these adverse effects during treatment.

Read All FAQs